#ASCO14 - Poster: Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo

CHICAGO, IL USA (UroToday.com) - Presented by Michael J. Morris,¹ Yohann Loriot,² Tomasz M. Beer,³ Celestia S. Higano,⁴ Andrew J. Armstrong,⁵ Cora N. Sternberg,⁶ Johann De Bono,⁷ Bertrand Tombal,⁸ Sarah B. Noonberg,⁹ Hank Mansbach,⁹ Suman Bhattacharya,⁹ Frank Perabo,¹⁰ De Phung,¹⁰ and Dana E. Rathkopf¹ at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

¹Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY USA
²Institut Gustave Roussy, University of Paris Sud, Villejuif, France
³OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR USA
⁴Seattle Cancer Care Alliance, University of Washington, Seattle, WA USA
⁵Duke University Medical Center Duke Cancer Institute Divisions of Medical Oncology and Urology, Duke University, Durham, NC USA
⁶San Camillo and Forlanini Hospitals, Rome, Italy
⁷Royal Marsden Hospital and Institute of Cancer Research, London, UK
⁸Cliniques Universitaires Saint-Luc, Brussels, Belgium
⁹Medivation Inc., San Francisco, CA USA
¹⁰Astellas Pharma Global Development, Inc., Northbrook, IL USA